NeoGraph Analytics
DiagnosticsNorth America2023 – 2032

Cancer Biopsy Market Size, Share and Trends Analysis

Global cancer biopsy market analysis shows $4.5B in 2023 growing at 6.8% CAGR to $8.7B by 2032. Key drivers: rising cancer incidence, precision oncology adoption, and AI integration in diagnostics.

Revenue, 2023

$4.5B

Forecast, 2032

$8.7B

CAGR, 2024-2032

6.8%

Report Coverage

North America

Code: cancer-biopsy-marketPublished: 2026Pages: 150+Format: PDF + Excel
01

Market Overview

The global cancer biopsy market is experiencing robust growth driven by rising cancer incidence, advancements in precision oncology, and increasing adoption of molecular diagnostics. The market is projected to expand at a CAGR of 6.8% from 2023 to 2032.

Market Stage

High growth

Adoption Level

Growing

Key Trends

Rise of liquid biopsy technologiesIntegration of AI in pathologyIncreasing demand for precision oncologyGrowing adoption of immunohistochemistry
02

Market Forecast & Data

Market Growth Forecast
2024-2032 · CAGR 6.8%

Base Year (2023)

$4.7B

Forecast (2032)

$8.7B

CAGR (2024-2032)

6.8%

Regional Market Analysis
Market share and growth rate by region

North America

#1
Share: 42.3%CAGR: 7.2%

Largest market: United States

Europe

#2
Share: 30.8%CAGR: 6.5%

Largest market: Germany

03

Market Dynamics

  • Rising global cancer incidence
  • Advancements in precision medicine
  • Increasing awareness of early cancer detection
  • Technological innovations in biopsy techniques
04

Market Segmentation

By End User

  • Hospitals
  • Diagnostic Laboratories
  • Cancer Centers
  • Research Institutes
05

Regional Analysis

1

North America

Lead: United States
CAGR: 7.2%Share: 42.3%

Dominant market due to advanced healthcare infrastructure, high reimbursement rates, and early adoption of innovative technologies.

2

Europe

Lead: Germany
CAGR: 6.5%Share: 30.8%

Strong growth driven by comprehensive healthcare systems and increasing investment in precision oncology initiatives.

3

Asia Pacific

Lead: China
CAGR: 9.1%Share: 24.7%

Fastest-growing region due to rising cancer incidence, expanding healthcare access, and government initiatives to improve cancer diagnostics.

Country-Level Analysis

CountryShareGrowth
United States
28.5%
+7.0%
China
12.3%
+10.2%
Germany
8.7%
+6.8%
06

Competitive Landscape

R

Roche Diagnostics

Switzerland

Leader27.1B

Dominates with comprehensive diagnostic portfolio including tissue and liquid biopsy platforms, immunohistochemistry, and NGS solutions.

Ventana DP200 Digital Pathology Systemcobas EGFR Mutation TestVivaCyte Liquid Biopsy Platform
A

Abbott Laboratories

USA

Challenger30.2B

Strong presence in digital pathology and liquid biopsy with FDA-approved platforms for oncology applications.

Alinity m SystemAbbott ID NOW COVID-19 TestVista Molecular Diagnostics Platform
Q

Qiagen

Germany

Follower

Specializes in sample preparation and molecular diagnostics for cancer biomarker testing.

B

Becton Dickinson

USA

Follower

Leading provider of biopsy needles and surgical instruments for tissue sampling.

T

Thermo Fisher Scientific

USA

Follower

Offers integrated solutions including IHC reagents, NGS, and digital pathology platforms.

S

Siemens Healthineers

Germany

Follower

Provides advanced imaging and digital pathology solutions for cancer diagnosis.

D

Danaher Corporation

USA

Follower

Through its Leica Biosystems subsidiary, offers tissue processing and pathology solutions.

07

Recent Developments

25
2025Roche

FDA clearance for VivaCyte Liquid Biopsy Platform for multi-cancer early detection

25
2025Thermo Fisher

Acquisition of Pathwork Diagnostics for enhanced molecular profiling

24
2024Abbott

Launch of Alinity i Digital Pathology Solution with AI-assisted tumor analysis

24
2024Qiagen

Partnership with IBM Watson Health for AI-driven biomarker interpretation

24
2024Becton Dickinson

Introduction of robotic biopsy system for improved sample quality

08

Regulatory Landscape

FDA's Class II/III device regulations for diagnostic equipmentEMA's In Vitro Diagnostic Regulation (IVDR) requirementsChina's NMPA approval processes for novel diagnostic testsCLIA certification requirements for clinical laboratories
09

Frequently Asked Questions

The cancer biopsy market was valued at $4.5 billion in 2023 and is projected to reach $8.7 billion by 2032.
The market is expected to grow at a compound annual growth rate (CAGR) of 6.8% from 2024 to 2032.
North America holds the largest market share at 42.3%, primarily driven by the United States.
Liquid biopsy techniques are the fastest-growing segment with a projected CAGR of 12.1% through 2032.